The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer
- 6 October 2010
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Pharmacology
- Vol. 10 (6), 620-628
- https://doi.org/10.1016/j.coph.2010.09.007
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Genome-Wide Analysis of Estrogen Receptor α DNA Binding and Tethering Mechanisms Identifies Runx1 as a Novel Tethering Factor in Receptor-Mediated Transcriptional ActivationMolecular and Cellular Biology, 2010
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast CancerCancer Prevention Research, 2010
- Minireview: Not Picking Pockets: Nuclear Receptor Alternate-Site Modulators (NRAMs)Molecular Endocrinology, 2010
- CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor α by cAMPGenes & Development, 2010
- Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast TissueClinical Cancer Research, 2010
- Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)Journal of Medicinal Chemistry, 2010
- Activity of fulvestrant in HER2-overexpressing advanced breast cancerAnnals Of Oncology, 2009
- Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST StudyJournal of Clinical Oncology, 2009
- The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistanceBreast Cancer Research and Treatment, 2008
- Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 SitesScience, 1997